Literature DB >> 35677987

Association of Symptomatic Hearing Loss with Functional and Cognitive Recovery 1 Year after Intracerebral Hemorrhage.

Jessica R Abramson1,2,3, Juan Pablo Castello1,2, Sophia Keins1,2,3, Christina Kourkoulis1,2,3, M Edip Gurol2, Steven M Greenberg2, Anand Viswanathan2, Christopher D Anderson1,2,3,4, Jonathan Rosand1,2,3, Alessandro Biffi1,2,3.   

Abstract

Entities:  

Year:  2022        PMID: 35677987      PMCID: PMC9194545          DOI: 10.5853/jos.2022.00836

Source DB:  PubMed          Journal:  J Stroke        ISSN: 2287-6391            Impact factor:   8.632


× No keyword cloud information.
Dear Sir: Survivors of intracerebral hemorrhage (ICH) are at high risk for poor functional and cognitive outcomes. At 12 months from the acute hemorrhage less than a third achieve functional independence, while over 25% are diagnosed with dementia and many more report milder cognitive deficits [1-3]. Hearing loss represents modifiable risk factor for functional decline cognitive dysfunction, yet it is often underdiagnosed and insufficiently addressed among individuals at risk [4]. We therefore sought to quantify the incidence of hearing loss among ICH survivors, identify associated risk factors, and determine whether it is associated with poor neurological recovery. We analyzed data for consecutive patients admitted to Massachusetts General Hospital between January 1st 2006 and December 31st 2017 with a spontaneous ICH diagnosis [5]. Admission CT scans were analyzed to determine ICH location and hematoma volume [2]. We used validated ordinal scales to evaluate overall cerebral small vessel disease, cerebral amyloid angiopathy (CAA), and hypertensive arteriopathy burden on brain magnetic resonance imaging (MRI) scans obtained according to a previously validated protocol [1]. We initially screened for diagnosis of hearing loss by analyzing participants’ electronic health records (EHR) using a natural language processing approach [6]. All hearing loss diagnoses were then confirmed by manual review of EHR. We captured information on functional performance status on the modified Rankin Scale (mRS) at discharge, 3 months, and 12 months after ICH [7]. We then subdivided participants in the following groups: (1) functional decline (i.e., higher mRS at 12 months vs. 3 months); (2) functional stability (i.e., same mRS at 12 months vs. 3 months); and (3) functional recovery (i.e., lower mRS at 12 months vs. 3 months) [8]. We captured cognitive recovery by combining manual review of EHR with results from the modified Telephone Interview for Cognitive Status (TICS-m), administered at 3 and 12 months after ICH as previously described [2]. Among individuals with cognitive impairment at 3 months (major or minor neurocognitive disorder), we identified those who experienced cognitive recovery at 12 months based on either: (1) resolution of cognitive deficits (i.e., return to normal cognition) or (2) improvement from major to minor neurocognitive impairment. We performed univariable and multivariable analyses to identify risk factors for hearing loss diagnosis. We then performed multivariable analyses of likelihood to experience functional or cognitive recovery among study participants. For functional recovery, we created an ordinal logistic regression model quantifying likelihood of experiencing decline, stability, or improvement in functional performance. For cognitive recovery, we created a logistic regression model quantifying likelihood of experiencing improvement in cognitive performance (as previously defined). Additional information on study inclusion and exclusion criteria, enrollment procedures, data collection, and statistical methods are provided in the Supplementary Methods. We initially screened a total of 1,339 consecutive ICH cases for inclusion in the present study. After application of exclusion and inclusion criteria (Supplementary Figure 1), we analyzed data for 737 ICH survivors. The majority of excluded participants (475/602, 78.9%) were excluded due to mortality within 1 year of the acute ICH. We identified 86 participants (11.7%) who received a diagnosis of hearing loss (Supplementary Table 1). In multivariable analyses, age, number of medical visits before ICH, number of anti-hypertensive medications used before ICH and CAA disease burden on MRI were independently associated with likelihood of receiving a diagnosis of hearing loss (Table 1). Among 737 participants, 60 (8.1%) experienced functional decline, 473 (64.2%) experienced functional stability, and 204 (27.7%) experienced functional recovery (Figure 1A). In multivariable analyses, hearing loss emerged as independently associated with functional recovery at 1 year from ICH (Table 2). At 3 months, 92 participants (12%) were diagnosed with minor neurocognitive disorder and 182 (25%) with major neurocognitive disorder, and were thus eligible for inclusion in subsequent analysis of cognitive recovery in the first year after ICH (Figure 1B). We found that 76/274 (28%) fulfilled criteria for cognitive recovery at 12 months from the initial hemorrhagic stroke event. In multivariable hearing loss was an independent risk factor for lower likelihood of cognitive recovery at 1 year from ICH (Table 2).
Table 1.

Multivariable analyses of risk factors for hearing loss among ICH survivors

VariableOR95% CI P
Age (/10 years)1.081.05–1.11<0.001
Race/Ethnicity (non-White)0.680.31–1.500.341
Male sex1.821.11–2.990.018
No. of medical visits (12 months before ICH)1.031.01–1.050.001
No. of antihypertensive medications
 NoneReferenceReferenceReference
 One1.430.75–2.710.279
 Two1.000.47–2.100.990
Three or more2.311.15–4.670.019
IVH volume (/10 cc)0.740.50–1.110.147
CAA MRI score (for 1 point increase)1.261.06–1.500.009

ICH, intracerebral hemorrhage; OR, odds ratio; CI, confidence interval; IVH, intraventricular hemorrhage; CAA, cerebral amyloid angiopathy; MRI, magnetic resonance imaging.

Figure 1.

Functional and cognitive recovery following intracerebral hemorrhage (ICH) among survivors with and without hearing loss. (A) Comparison of distribution in modified Rankin Scale (mRS) scores at 3 months vs. 12 months among ICH survivors without (top bars) vs. with (bottom bars) hearing loss. Numbers in the bar section refer to count of individuals within each subgroup defined by mRS scores. (B) Comparison of distribution in cognitive status diagnoses at 3 months vs. 12 months among ICH survivors without (top bars) vs. with (bottom bars) hearing loss. Numbers in the bar section refer to count of individuals within each subgroup defined by diagnosis of major neurocognitive disorder (NCD), minor NCD, or normal cognition at each time point.

Table 2.

Multivariable models for functional and cognitive recovery after ICH

VariableFunctional recovery (ordinal logistic regression)
Cognitive recovery (logistic regression)
OR95% CI P OR95% CI P
Age (/yr)1.000.99–1.020.7321.000.97–1.020.955
Race/Ethnicity (non-White)0.980.62–1.540.9210.460.21–1.030.058
Male sex1.451.02–2.050.0381.260.69–2.290.453
Discharge mRS: 4 to 50.250.17–0.36<0.001---
ICH location: lobar---0.430.23–0.820.010
ICH volume (/10 cc)---0.880.78–1.000.050
GCS >8 at presentation---2.961.09–8.040.034
CSVD MRI score (/1 point increase)0.340.29–0.39<0.0010.740.61–0.890.002
Hearing loss0.430.25–0.760.0040.320.13–0.790.014

ICH, intracerebral hemorrhage; OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; GCS, Glasgow Coma Scale; CSVD, cerebral small vessel disease; MRI, magnetic resonance imaging.

In summary, we leveraged data from a single-center study of ICH survivors to investigate the prevalence of hearing loss in this patient group at high risk for poor functional and cognitive outcomes. We found that over 10% of them displayed evidence of symptomatic hearing loss, with multiple factors contributing to individuals’ likelihood of receiving this diagnosis. We specifically identified a novel association with CAA disease severity, as quantified via a validated MRI scoring system. Furthermore, we found that hearing loss was associated with lower likelihood of good functional and cognitive outcomes at 1 year after ICH. Overall, our results indicate hearing loss might serve as a key, underappreciated barrier preventing survivors of primary ICH from achieving their maximum recovery potential. Additional studies will be required to investigate mechanisms accounting for this association, including determining: (1) impacts engagement with post-stroke rehabilitation effort; (2) serves as a surrogate marker of underlying brain health and its expected impact on recovery; and (3) directly contributes to decreased neuronal plasticity [9]. Our study has several limitations. Our approach likely resulted in imprecise capture of hearing performance—including potential for incorrect hearing loss diagnoses and limited ability to quantify etiology, laterality, severity, and treatment course of hearing impairment. We also utilized phone-based cognitive testing, which could potentially introduce bias towards worse cognitive performance among participants with hearing loss. To address this possibility, we conducted a validated screening of hearing performance prior to phone-based cognitive testing, as in prior studies [2]. We also conducted a parallel analysis using EHR-derived cognitive performance data to bolster our findings. Finally, we leveraged data from a single, tertiary care center with dedicated expertise in ICH management. This may have therefore introduced referral and severity bias, potentially limiting generalizability to ICH survivors at large.
  9 in total

1.  Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage.

Authors:  Marije R Benedictus; Anaïs Hochart; Costanza Rossi; Gregoire Boulouis; Hilde Hénon; Wiesje M van der Flier; Charlotte Cordonnier
Journal:  Stroke       Date:  2015-08-13       Impact factor: 7.914

Review 2.  Age-Related Hearing Loss: Innovations in Hearing Augmentation.

Authors:  Yona Vaisbuch; Peter Luke Santa Maria
Journal:  Otolaryngol Clin North Am       Date:  2018-05-04       Impact factor: 3.346

3.  Comparison of telephone and face-to-face assessment of the modified Rankin Scale.

Authors:  Paula M Janssen; Nora A Visser; Sanne M Dorhout Mees; Catharina J M Klijn; Ale Algra; Gabriel J E Rinkel
Journal:  Cerebrovasc Dis       Date:  2009-12-01       Impact factor: 2.762

4.  Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage.

Authors:  Meredith P Murphy; Joji B Kuramatsu; Audrey Leasure; Guido J Falcone; Hooman Kamel; Lauren H Sansing; Christina Kourkoulis; Kristin Schwab; Jordan J Elm; M Edip Gurol; Huy Tran; Steven M Greenberg; Anand Viswanathan; Christopher D Anderson; Stefan Schwab; Jonathan Rosand; Fu-Dong Shi; Steven J Kittner; Fernando D Testai; Daniel Woo; Carl D Langefeld; Michael L James; Sebastian Koch; Hagen B Huttner; Alessandro Biffi; Kevin N Sheth
Journal:  Stroke       Date:  2018-11       Impact factor: 7.914

5.  Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.

Authors:  Alessandro Biffi; Christopher D Anderson; Thomas W K Battey; Alison M Ayres; Steven M Greenberg; Anand Viswanathan; Jonathan Rosand
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

6.  Risk Factors Associated With Early vs Delayed Dementia After Intracerebral Hemorrhage.

Authors:  Alessandro Biffi; Destiny Bailey; Christopher D Anderson; Alison M Ayres; Edip M Gurol; Steven M Greenberg; Jonathan Rosand; Anand Viswanathan
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

7.  Association of Cerebral Small Vessel Disease and Cognitive Decline After Intracerebral Hemorrhage.

Authors:  Marco Pasi; Lansing Sugita; Li Xiong; Andreas Charidimou; Gregoire Boulouis; Thanakit Pongpitakmetha; Sanjula Singh; Christina Kourkoulis; Kristin Schwab; Steven M Greenberg; Christopher D Anderson; M Edip Gurol; Jonathan Rosand; Anand Viswanathan; Alessandro Biffi
Journal:  Neurology       Date:  2020-10-16       Impact factor: 9.910

Review 8.  Hearing and dementia: from ears to brain.

Authors:  Jeremy C S Johnson; Charles R Marshall; Rimona S Weil; Doris-Eva Bamiou; Chris J D Hardy; Jason D Warren
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.